17327-22-9

Usage

Uses

Used in Pharmaceutical Industry:
5,6-Dihydro-4-methoxy-2H-pyran is used as a reagent for the protection of chiral alcohols, which is crucial in the synthesis of various pharmaceutical compounds. Its ability to protect nucleoside hydroxyl functions allows for the selective synthesis of complex molecules with specific biological activities.
Used in Chemical Research:
In the field of chemical research, 5,6-Dihydro-4-methoxy-2H-pyran is used as a reagent for the solid-phase synthesis of oligoribonucleotides. This application is significant for the development of new drugs and the study of molecular biology, as oligoribonucleotides can be used as therapeutic agents and research tools.
Used in Synthesis of Oligoribonucleotides:
5,6-Dihydro-4-methoxy-2H-pyran is used as a key reagent in the solid-phase synthesis of a series of oligoribonucleotides. This process is essential for the development of new drugs and the study of genetic information, as oligoribonucleotides can be used to manipulate gene expression and understand the function of specific genes.
Overall, 5,6-Dihydro-4-methoxy-2H-pyran is a versatile compound with applications in various industries, including pharmaceuticals, chemical research, and the synthesis of oligoribonucleotides. Its ability to protect chiral alcohols and nucleoside hydroxyl functions makes it a valuable tool in the development of new drugs and the advancement of scientific knowledge.

InChI:InChI=1/C6H10O2/c1-7-6-2-4-8-5-3-6/h2H,3-5H2,1H3

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 28218-71-5 4,4-dimethoxytetrahydro-4H-pyran 

Downstream Products

• 83906-43-8 3',5'-di-O-acetyl-2'-O-(4-methoxytetrahydropyran-4-yl)-N²-benzoylguanosine 
• 119874-37-2 1-O-(tert-butyldiphenylsilyl)-4-O-(4-methoxytetrahydropyran-4-yl)-2,3:5,6-di-O-isopropylidene-D-myo-inositol 
• 119874-37-2 3-O-(tert-butyldiphenylsilyl)-6-O-(4-methoxytetrahydropyran-4-yl)-1,2:4,5-di-O-isopropylidene-D-myo-inositol 
• 129678-67-7 1-<5-O-(tert-butyldiphenylsilyl)-3-deoxy-3-C-(4,5-dihydro-5-methyl-1,3,5-dithiazin-2-yl)-2-O-(4-methoxytetrahydropyran-4-yl)-β-D-arabino-pentofuranosyl>uracil 
• 129678-68-8 1-<5-O-(tert-butyldiphenylsilyl)-3-deoxy-3-C-(4,5-dihydro-5-methyl-1,3,5-dithiazin-2-yl)-2-O-(4-methoxytetrahydropyran-4-yl)-β-D-arabino-pentofuranosyl>thymine 
• 60943-92-2 2'-O-(4-methoxytetrahydropyran-4-yl)-N²-benzoylguanosine 
• 86610-78-8 3'-O-(4-methoxytetrahydropyran-2-yl)-5'-O-<4,4',4''-tris(benzoyloxy)trityl>thymidine 
• 77451-35-5 N⁴-benzoyl-2'-O-(4-methoxytetrahydropyran-4-yl)cytidine 
• 77451-34-4 5'-O-(o-dibromomethylbenzoyl)-2'-O-methoxytetrahydropyranyl-6-N-benzoyladenosine 
• 155834-44-9 N⁶-<2-(4-nitrophenyl)ethoxycarbonyl>-2'-O-(tetrahydro-4-methoxy-2H-pyran-4-yl)-3',5'-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)adenosine 
• 80235-20-7 2'-O-(4-methoxytetrahydropyran-4-yl)-N²-diphenylacetylguanosine 
• 115561-35-8 {9-[(2R,3S,4R,5R)-5-(tert-Butyl-dimethyl-silanyloxymethyl)-3-[(4-methoxy-phenyl)-diphenyl-methoxy]-4-(4-methoxy-tetrahydro-pyran-4-yloxy)-tetrahydro-furan-2-yl]-9H-purin-6-yl}-[(4-methoxy-phenyl)-diphenyl-methyl]-amine 
• 155834-45-0 N²-<2-(4-nitrophenyl)ethoxycarbonyl>-O⁶-<2-(4-nitrophenyl)ethyl>-2'-O-(tetrahydro-4-methoxy-2H-pyran-4-yl)-3',5'-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)guanosine 
• 155834-46-1 N⁴-<2-(4-nitrophenyl)ethoxycarbonyl>-2'-O-(tetrahydro-4-methoxy-2H-pyran-4-yl)-3',5'-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)cytidine 

Relevant academic research and scientific papers

SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

Efficient preparation of 4-methoxy-5,6-dihydro-2H-pyran

We report the efficient synthesis of 4-methoxy-5,6-dihydro-2H-pyran (MDHP) via the TiCl4 driven elimination of MeOH from 4,4-dimethoxytetrahydropyran. The previous difficulty of preparing MDHP restricted the wider use of 4-methoxytetrahydropyran-4-yl (MTHP) acyclic acetals, which have desirable protecting group properties when compared to more commonly used MOM- and THP-acetals. The behaviour of the elimination on related acetals is also examined.

Process for synthetizing polyoxyalkyleneglycol-mono-ethers

Polyoxyalkylene-glycol-monoethers containing a desired number of oxyalkylene units are prepared by starting from a linear or branched aliphatic alcohol, preferably a primary linear aliphatic alcohol, or from a mono-hydroxy phenol, preferably bearing alkyl--substituents on its ring, and mono-halogenated linear oxyalkylene glycols, wherein the halogen is in a terminal position and the hydroxy group is protected by known means, under basic conditions, with polyoxyalkyleneglycol-monoethers being obtained, which contain a protected hydroxy group, from which the protecting group is removed by means of a treatment under acidic conditions, thus the desired product being obtained, which is useful as a non-ionic surfactant, in particular in the cosmetic and/or pharmaceutical field.